Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Alligator Bioscience
Alligator Bioscience
Activities:
Regulatory
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Aptevo and Alligator Bioscience develop immunotherapy candidate
Aptevo Therapeutics and Alligator Bioscience begin investigational new drug development to investigate the bispecific immunotherapy candidate ALG.APV-527
Ingredients
Cobra Biologics and Alligator Bioscience extend drug development partnership
Project will deliver second cell line to manufacture immuno-oncology antibody ADC-1015 following ADC-1013 success
Research & Development
J&J announces immuno-oncology collaboration with Alligator Bioscience
Alligator will complete the current Phase I study and Janssen will be responsible for all subsequent product development
Ingredients
Alligator Bioscience benefits from Cobra’s maxXpress platform
Cobra developed the cell line to express agonistic CD40 antibodies for an immuno-oncology application using its maxXpress platform
Manufacturing
Cobra to produce monoclonal antibody products for Alligator
Will provide cell line development, scale-up, GMP supplies and stability studies
Subscribe now